Lisata Therapeutics
110 Allen Road, 2nd Floor
Basking Ridge
New Jersey
07920
United States
Tel: 908-842-0100
443 articles about Lisata Therapeutics
-
Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020
11/10/2020
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announces its presentation at American Heart Association’s (“AHA”) Scientific Sessions, being held virtually November 13-17, 2020.
-
Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in November
11/4/2020
- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in three upcoming virtual investor conferences during November 2020. November 11-16, 2020 LSX Virtual Inv€$tival Showcase November 17-19, 2020 Jefferies Virtual London Healthcare Conferenc e Novemb
-
Caladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to Board of Directors
11/2/2020
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced the appointment of Anne Whitaker to its Board of Directors. Ms. Whitaker is a seasoned healthcare executive bringing to Caladrius 28 years of experience in the life science industry, including senior leadership roles
-
Caladrius Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time
10/29/2020
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that the Company will report its third quarter financial results for the three and nine months ended September 30, 2020 on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time. Live Conference Call and We
-
Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360°
10/21/2020
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Medical Officer, Douglas W. Losordo, M.D., FACC, FAHA, will participate in 8th annual Chief Medical Officer Summit 360°
-
Clinical Catch-Up: October 12-16
10/19/2020
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
-
Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage
10/8/2020
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced that it has opened its proof-of-concept study of CLBS119 as a treatment for COVID-19-induced lung damage and begun screening prospective patients for inclusion at NYU Langone Health.
-
Caladrius Biosciences to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa
10/7/2020
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Medical Officer, Douglas W. Losordo, M.D., FACC, FAHA, will present at the Alliance for Regenerative Medicine’s (ARM) Cell and Gene Meeting on the Mesa, being held virtually on October 12-16, 2020. T
-
Caladrius Biosciences to Present at the BIO Investor Forum Digital
10/6/2020
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Executive Officer, David J. Mazzo, Ph.D., will present a company overview at the BIO Investor Forum, being held virtually on October 13-15, 2020. This presentation will be available on demand for BIO I
-
Caladrius Biosciences to Present at the Life Sciences Investor Forum on September 17th
9/14/2020
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that management will present a company overview at the Virtual Life Sciences Investor Forum, which is being held on Thursday, September 17, 2020.
-
Caladrius Biosciences to Participate in Landmark’s 10th Annual Investing for Cures Virtual Forum
9/10/2020
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in Landmark’s 10th Annual Investing for Cures Virtual Forum being held September 16-17, 2020.
-
Caladrius Biosciences Announces Registration of HONEDRA® Trademark and New Patent in Japan
9/9/2020
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it has received trademark registration from the Japan Patent Office (“JPO”) for the Company’s use of HONEDRA® as the brand name for CLBS12,
-
Caladrius Biosciences to Present at H.C. Wainwright 22nd Annual Global Investment Virtual Conference
9/8/2020
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the H.C. Wainwright 22 nd Annual Global Investment Conference, held virtually this year, September 14-16, 2020. Presentation Details: Date & Time: Tuesday, Septembe
-
Caladrius Biosciences to Participate in the Advanced Therapies Congress & Expo 2020
9/3/2020
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the Advanced Therapies Congress & Expo being held virtually September 8-11, 2020. Title: Repair of the microcirculation reverses ischemic tissue damage Presenter: Dougl
-
Caladrius Biosciences to Present at the LD 500 Virtual Conference on September 1, 2020 at 11:40 AM Eastern Time
8/27/2020
Caladrius Biosciences, Inc. today announced that management has been invited to present at the LD 500 virtual investor conference being held September 1-4, 2020.
-
Caladrius Biosciences Provides Corporate Update and Reports 2020 Second Quarter Financial Results
8/13/2020
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, provides a corporate update and reports financial results for the three and six months ended June 30, 2020.
-
Caladrius Biosciences to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 13, 2020
8/6/2020
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, today announced that it will report financial results for the three and six months ended June 30, 2020 after the close of the U.S. financial markets on Thursday, August 13, 2020. Caladrius management will host a conference c
-
BioSpace Movers & Shakers, July 31
7/31/2020
Biopharma and life science companies strengthen their leadership teams and board with these Movers & Shakers. -
Caladrius Biosciences Appoints Dr. Michael H. Davidson to Board of Directors
7/28/2020
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, today announced the appointment of Michael H. Davidson, MD to its Board of Directors. Dr. Davidson, an industry leader and expert in preventative cardiology and lipidology, is the Founder and Chief Scientific Officer of Corvi